Cargando…

Molecular Classification of Triple-Negative Breast Cancer

Tumor heterogeneity of triple-negative breast cancer (TNBC) has been the main barrier in conquering breast cancer. To dissect the molecular diversity of TNBC and discover therapeutic targets for TNBC, the molecular classification of TNBC is a prioritized issue in research area. Accordingly, recent s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Sung Gwe, Kim, Seung Jun, Kim, Cheungyeul, Jeong, Joon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053306/ https://www.ncbi.nlm.nih.gov/pubmed/27721871 http://dx.doi.org/10.4048/jbc.2016.19.3.223

Ejemplares similares

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2021)

SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
por: Baek, Seung Ho, et al.
Publicado: (2022)

Comparison of Programmed Cell Death Ligand 1 Status between Core Needle Biopsy and Surgical Specimens of Triple-Negative Breast Cancer
por: Choi, Hyungwook, et al.
Publicado: (2023)

The nature of triple-negative breast cancer classification and antitumoral strategies
por: Kim, Songmi, et al.
Publicado: (2020)

Cellular inhibitor of apoptosis protein 2 promotes the epithelial-mesenchymal transition in triple-negative breast cancer cells through activation of the AKT signaling pathway
por: Jo, Su Ji, et al.
Publicado: (2017)

Risk Factors for a False-Negative Result of Sentinel Node Biopsy in Patients with Clinically Node-Negative Breast Cancer
por: Lee, Seung Ah, et al.
Publicado: (2018)

Prospective Evaluation of the Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Negative Axillary Conversion after Neoadjuvant Chemotherapy
por: Lee, Hy-De, et al.
Publicado: (2015)

Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review
por: Lu, Boya, et al.
Publicado: (2023)

Survival Benefit of Zoledronic Acid in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors
por: Ahn, Sung Gwe, et al.
Publicado: (2014)

RNF208, an estrogen-inducible E3 ligase, targets soluble Vimentin to suppress metastasis in triple-negative breast cancers
por: Pang, Kyoungwha, et al.
Publicado: (2019)

Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2015)

Theranostics for Triple-Negative Breast Cancer
por: Choi, Hyeryeon, et al.
Publicado: (2023)

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
por: Park, Ji Hyun, et al.
Publicado: (2018)

Impact of Triple-Negative Breast Cancer Phenotype on Prognosis in Patients with Stage I Breast Cancer
por: Kim, Jeong Eun, et al.
Publicado: (2012)

Radiotherapy-Induced High Neutrophil-to-Lymphocyte Ratio is a Negative Prognostic Factor in Patients with Breast Cancer
por: Yoon, Chang Ik, et al.
Publicado: (2020)

Molecular classification of triple-negative tumors
por: Prat, A, et al.
Publicado: (2011)

Molecular Classification Models for Triple Negative Breast Cancer Subtype Using Machine Learning
por: Bissanum, Rassanee, et al.
Publicado: (2021)

Patterns and Biologic Features of p53 Mutation Types in Korean Breast Cancer Patients
por: Kim, Hyung Won, et al.
Publicado: (2014)

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Triple-negative breast cancer molecular subtyping and treatment progress
por: Yin, Li, et al.
Publicado: (2020)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
por: Ibragimova, Marina K., et al.
Publicado: (2021)

Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
por: Ryu, Won-Ji, et al.
Publicado: (2021)

Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay
por: Ahn, Sung Gwe, et al.
Publicado: (2017)

Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
por: Ji, Jung Hwan, et al.
Publicado: (2022)

Metastasis-Free Interval Is Closely Related to Tumor Characteristics and Has Prognostic Value in Breast Cancer Patients with Distant Relapse
por: Kim, Hee Jun, et al.
Publicado: (2015)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy
por: Peddi, Parvin F., et al.
Publicado: (2012)

Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer
por: Nakhjavani, Maryam, et al.
Publicado: (2019)

Molecular subtypes and precision treatment of triple-negative breast cancer
por: Zhao, Shen, et al.
Publicado: (2020)

Triple-negative breast cancer: A run-through of features, classification and current therapies
por: Manjunath, Meghana, et al.
Publicado: (2021)

Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
por: Bae, Soong June, et al.
Publicado: (2021)

In vivo dosimetry and acute toxicity in breast cancer patients undergoing intraoperative radiotherapy as boost
por: Lee, Jason Joon Bock, et al.
Publicado: (2017)

Classification of triple-negative breast cancers based on Immunogenomic profiling
por: He, Yin, et al.
Publicado: (2018)

Long-Term Survival Analysis of Korean Breast Cancer Patients at a Single Center: Improving Outcome Over Time
por: Ahn, Sung Gwe, et al.
Publicado: (2014)

Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance
por: Kim, Hyungjoo, et al.
Publicado: (2022)

Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2017)

Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer
por: Zhang, Zhiying, et al.
Publicado: (2023)

Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
por: Park, So-Yeon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k14lv1mvi9bria1io0m5v0k5e7